Loading, Please Wait...

CST: 09/12/2019 14:54:30   

GenMark Diagnostics Reports Second Quarter 2019 Results

125 Days ago

CARLSBAD, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2019.

Highlights

  • Recognized total revenue of $18.4 million 
    -- ePlex revenue of $12.0 million represented 66% of total revenue 
    -- ePlex revenue grew 70% compared to the prior year period
  • Placed 45 net new ePlex analyzers, expanding the global installed base to 438 placements 
    -- ePlex installed base grew 64% compared to the prior year period
  • Achieved gross margin of 36%, a 600-basis point increase over the prior year period
  • Raised full year 2019 gross margin guidance to a range of 31% to 33%

“In the second quarter, we delivered strong commercial results and increased operational efficiency, while also continuing to advance innovation and future product development. The significant revenue growth and installed base expansion of our ePlex system, underscored its continued strong adoption across a wide range of healthcare settings in the marketplace. Furthermore, we made excellent progress driving manufacturing efficiencies in the quarter. Once again, we saw strong improvement in ePlex gross margin, giving us further confidence that we can reach our overall gross margin target of 60%-plus over the next 2-3 years,” said Hany Massarany, President and Chief Executive Officer. “I believe that the combination of our ePlex platform, its differentiated test menu and broad market adoption, together with the continued strong execution of our commercial teams, signal a very exciting inflection point in our business with a long runway for future growth.”

Second Quarter Financial Results
Revenue was $18.4 million in the second quarter of 2019, an increase of 23% versus $14.9 million in the second quarter of 2018.  Gross profit was $6.6 million, or 36% of revenue, compared with $4.4 million, or 30% of revenue in the same period of 2018.

Operating expenses for the second quarter of 2019 were $18.5 million compared to $20.2 million in the same period of 2018.  The decrease was largely due to reduced development expenses related to the completion of the ePlex BCID clinical studies, partially offset by increased investment in the commercial function to support the BCID launch. Expense in the quarter also included investment in R&D to support key technology and product improvement initiatives, primarily attributable to the cost of ePlex consumables required to support these projects. 

Loss per share was $0.23 for the second quarter of 2019, compared to a $0.30 loss per share in the second quarter of 2018.

Cash and investments were $41.4 million as of June 30, 2019.

Updated Guidance for Full Year 2019
GenMark continues to expect total revenue for the full year 2019 to be in the range of $85 million to $90 million.

The Company also reiterated global ePlex placements are expected to range from 170 to 190 net new analyzers with an annuity per analyzer of $135,000 to $145,000. 

Gross margin is now expected to be in the 31% to 33% range compared to prior guidance of 28% to 30%. The Company continues to expect operating expenses to be approximately $65 million to $70 million.

Cash usage continues to be projected in the range of $25 million to $30 million.

Webcast and Conference Call Information
GenMark will be hosting a conference call to discuss second quarter results in further detail on Monday, August 5, 2019 starting at 4:30 p.m. ET. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (International) and use the conference ID number 7472679 approximately five minutes prior to the start time.

About GenMark Diagnostics
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections.  For more information, visit www.genmarkdx.com.

Safe Harbor Statement
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect the Company’s future operating results and financial position. Such statements, including, but not limited to, those regarding its future financial performance, achievement of profitability targets, plans and objectives of management, and the timely and effective commercialization and clinical impact of the Company’s ePlex system, are all subject to risks and uncertainties that could cause actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, GenMark’s ability to successfully commercialize our ePlex system and its related test menu in a timely manner, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, the Company’s ability to successfully expand sales of its product offerings outside the United States, and third-party payor reimbursement to its customers, as well as other risks and uncertainties described under the “Risk Factors” in GenMark’s public filings with the Securities and Exchange Commission. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Investor Relations Contact                                                             
Leigh Salvo                                         
(415) 937-5404   
ir@genmarkdx.com

GENMARK DIAGNOSTICS, INC. 
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS 
(In thousands, except par value)

  June 30,
 2019
  December 31,
 2018
ASSETS:
Current Assets:      
Cash and cash equivalents $ 23,733     $ 36,286  
Short-term marketable securities 17,627     8,882  
Accounts receivable, net of allowances of $107 and $75, respectively 6,756     11,534  
Inventories, net 9,912     10,244  
Prepaid expenses and other current assets 2,085     1,483  
Total current assets 60,113     68,429  
       
Property and equipment, net 18,927     21,070  
Intangible assets, net 1,727     2,023  
Restricted cash 758     758  
Noncurrent operating lease right-of-use assets 4,883      
Other long-term assets 766     701  
Total assets $ 87,174     $ 92,981  
       
LIABILITIES AND STOCKHOLDERS' EQUITY:
Current liabilities:      
Accounts payable $ 8,390     $ 9,886  
Accrued compensation 5,349     7,358  
Current operating lease liability 1,815      
Other current liabilities 2,167     3,043  
Total current liabilities 17,721     20,287  
       
Deferred rent     2,996  
Long-term debt 48,271     36,042  
Noncurrent operating lease liability 6,339      
Other noncurrent liabilities 62     109  
Total liabilities 72,393     59,434  
       
Stockholders' equity:      
Preferred stock, $0.0001 par value; 5,000 authorized, none issued      
Common stock, $0.0001 par value; 100,000 authorized; 57,430 and 56,240 shares issued and outstanding, respectively 6     6  
Additional paid-in capital 506,949     500,344  
Accumulated deficit (492,271 )   (466,883 )
Accumulated other comprehensive income 97     80  
Total stockholders’ equity 14,781     33,547  
Total liabilities and stockholders’ equity $ 87,174     $ 92,981  
               

GENMARK DIAGNOSTICS, INC. 
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 
(In thousands, except per share data)

  Three Months Ended   Six Months Ended
  June 30,   June 30,
  2019   2018   2019   2018
Revenue:              
Product revenue $ 18,220     $ 14,867     $ 39,591     $ 35,443  
License and other revenue 154     74     316     143  
Total revenue 18,374     14,941     39,907     35,586  
Cost of revenue 11,801     10,527     27,471     27,007  
Gross profit 6,573     4,414     12,436     8,579  
Operating expenses:              
Sales and marketing 5,803     5,187     11,712     10,589  
General and administrative 4,931     4,547     9,452     8,680  
Research and development 7,749     10,482     14,092     15,902  
Total operating expenses 18,483     20,216     35,256     35,171  
Loss from operations (11,910 )   (15,802 )   (22,820 )   (26,592 )
Other income (expense):              
Interest income 179     202     312     389  
Interest expense (1,528 )   (797 )   (2,804 )   (1,585 )
Other income (expense) (4 )   (90 )   (15 )   (102 )
Total other income (expense) (1,353 )   (685 )   (2,507 )   (1,298 )
Loss before provision for income taxes (13,263 )   (16,487 )   (25,327 )   (27,890 )
Income tax expense 45     34     61     54  
Net loss $ (13,308 )   $ (16,521 )   $ (25,388 )   $ (27,944 )
Net loss per share, basic and diluted $ (0.23 )   $ (0.30 )   $ (0.45 )   $ (0.50 )
Weighted average number of shares outstanding, basic and diluted 57,171     55,547     56,878     55,377  
               
Other comprehensive loss:              
Net loss $ (13,308 )   $ (16,521 )   $ (25,388 )   $ (27,944 )
Other comprehensive income/(loss):              
Foreign currency translation adjustments, net of tax 15     (14 )   9     20  
Net unrealized gains on marketable securities, net of tax 6     15     8     23  
Total other comprehensive income 21     1     17     43  
Total comprehensive loss $ (13,287 )   $ (16,520 )   $ (25,371 )   $ (27,901 )
                               


GENMARK DIAGNOSTICS, INC. 
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 
(In thousands)

  Six Months Ended
 June 30,
  2019   2018
Operating activities:      
Net loss $ (25,388 )   $ (27,944 )
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 3,616     3,507  
Net amortization/(accretion) of premiums/discounts on investments (98 )   (78 )
Amortization of deferred debt issuance costs 816     583  
Stock-based compensation 5,711     5,799  
Provision for bad debt 46     34  
Non-cash inventory adjustments 897     809  
Other non-cash adjustments 125     (13 )
Changes in operating assets and liabilities:      
Accounts receivable 4,720     3,501  
Inventories (1,387 )   353  
Prepaid expenses and other assets (784 )   340  
Accounts payable (1,143 )   (1,853 )
Accrued compensation (2,490 )   (853 )
Other current and non-current liabilities (257 )   (622 )
Net cash used in operating activities (15,616 )   (16,437 )
Investing activities:      
Purchases of property and equipment (467 )   (924 )
Purchases of marketable securities (19,440 )   (23,622 )
Maturities of marketable securities 10,800     42,600  
Net cash (used in) provided by investing activities (9,107 )   18,054  
Financing activities:      
Proceeds from issuance of common stock 464     535  
Principal repayment of borrowings (35,140 )   (45 )
Proceeds from borrowings 50,000      
Payments associated with debt issuance (3,588 )   (20 )
Proceeds from stock option exercises 432     22  
Net cash provided by financing activities 12,168     492  
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 2     28  
Net increase (decrease) in cash, cash equivalents, and restricted cash (12,553 )   2,137  
Cash, cash equivalents, and restricted cash at beginning of year 37,044     27,512  
Cash, cash equivalents, and restricted cash at end of period $ 24,491     $ 29,649  
Non-cash investing and financing activities:      
Transfer of systems to property and equipment from inventory $ 822     $ 956  
Property and equipment included in accounts payable $ 18     $ 168  
Supplemental cash flow information:      
Cash paid for income taxes, net $ 104     $ 113  
Cash paid for interest $ 1,837     $ 1,003  

Is your business listed correctly on America’s largest city directory network of 1,000 portals?